Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Icahn vs. Illumina: The CEO’s Job—and Icahn’s Reputation—Are on the Line

Por: MarketWatch Business May 25, 2023

thumbnail

Illumina is holding its annual meeting at 1 p.m. Eastern time, at which the results of the proxy vote will be announced. The meeting will be held virtually, and is only open to shareholders. The stakes are high for Icahn, who needs a win. The Wall Street lion is facing an from a prominent short seller, a by the Financial Times that bad investment decisions cost his investment fund $9 billion over six years, and The stakes are high, too, for... + full article



Similar News

Illumina ordered by FTC to unwind $7b Grail deal from 2021

The Boston Globe USA Business April 04, 2023

thumbnailIllumina Inc. was ordered to unwind its $7 billion acquisition of cancer startup Grail by the Federal Trade Commission, an uncommon move by antitrust regulators who said the deal raises competition concerns for cancer testing.The FTC’s 4-0 decision announced Monday overturned... + más

FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC


F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition

The New York Times USA Business April 03, 2023

thumbnailThe Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más

FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC


FTC orders Illumina to unwind $7B deal for cancer test developer Grail

Fox Business USA Business April 03, 2023

thumbnailCheck out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina... + más

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC

F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition | The New York Times


What Are the Duties of A Trustee?

Forbes USA Business March 27, 2023

thumbnailLight Bulbs Concept Shining ETHICS, RESPECT, HONESTY and INTEGRITYgetty Previously, I wrote on in some detail, but did not go into the duties the Trustee of a Trust owes to the Trust’s beneficiary. To summarize, a Trust is an agreement written by the owner of the property,... + más

Selecting The Right Trustee To Manage Your Trust | Forbes

Author Post: Using Land Trusts For Anonymity And Asset Protection | Forbes


Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal

CNBC USA Health March 24, 2023

thumbnailIn this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC

Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC


Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal

CNBC USA Health March 21, 2023

thumbnailIn this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más

Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC

Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC


Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle

CNBC USA Business March 18, 2023

thumbnailBusiness: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC

Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC



About iurex | Privacy Policy | Disclaimer |